Press releases //

IntegraGen Collaborating with FIRE-3 Clinical Trial Investigators to Study hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker

IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.

Link to press (…)  » 

Press releases //

Results from sequencing of 193 liver tumors performed by IntegraGen identifies potential role of a new virus in the development of liver cancer

IntegraGen announces a publication in Nature Genetics reporting the role of adeno-associated virus type 2 (AAV2)  virus in the development of liver cancer. Professor Jessica Zucman-Rossi and her colleagues at Inserm Unit 1162 in Paris, supported by expert sequencing services from IntegraGen, identified the role of AAV2, a (…)  » 

Press releases //

IntegraGen Reports Revenue for First Half of 2015


IntegraGen today announced its sales for the first half 2015. Sales for IntegraGen’s business totaled € 2.6 million as of June 30, 2015, up 1% compared to the first half of 2014. The company also reported that it experienced a substantial growth in new projects during the first half of 2015 increasing by (…)  » 

Press releases //

IntegraGen presents positive data from two new studies on miR-31-3p biomarker at ASCO 2015


Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with (…)  »